PHARMACODYNAMIC AND PHARMACOKINETIC NEOADJUVANT STUDY OF HEDGEHOG PATHWAY INHIBITOR SONIDEGIB (LDE-225) IN MEN WITH HIGH-RISK LOCALIZED PROSTATE CANCER UNDERGOING PROSTATECTOMY